Join DIA for our first webinar in the DIA DIRECT: COVID-19 Virtual Series!
In challenging times such as these, staying informed is key. Hear from experts in China, from across various healthcare product development functions, on steps being taken to ensure the safety and efficacy of clinical trials continuing through this pandemic.
Panelists:
Jingsong Wang, MD, PhD (Moderator)
- Founder, Chairman, and CEO, Harbour BioMed
- Chair, DIA Advisory Council of China
Zhongyuan Xu, Professor
- Director, National Drug Clinical Trial Institution for the South Hospital & Center for Drug Clinical Trials and Phase I Clinical Research, Nanfang Hospital of Southern Medical University
- Chairman, the Special Committee for Drug Clinical Evaluation and Research, Chinese Pharmaceutical Association
- Founder, China Forums of Clinical Research, Capacity Building, and Human Research Participants Protection (CCHRPP)
Hannah Chen, MD
- Consultant, Beijing Xiao Tong Ming Da Technology Ltd.
- Member, DIA Advisory Council of China
Jessica Liu, MD
- VP, Head of International Business, Tigermed Co. Ltd
- Former CEO, DreamCIS, Korea., One Tigermed Company
- Member, DIA Advisory Council of China
Qi Lu
- Director, Ethics Committee Office, Renji Hospital, Shanghai Jiaotong University School of Medicine
- Deputy Secretary-General, Shanghai Medical Ethics SocietyMember and Secretary, Shanghai
- Medical Association, Research Ethics Branch
- Member, DIA Advisory Council of China
Fan Xia, PhD
- Head of Statistics, Zai Lab
- DIA Young Member of the Advisory Council of China
Jing Chen
- QA Director, LinkStar
Yue Wang
- Vice President, SMO ClinPlus Co., Ltd.
- Vice Chair, DIA China SMO Community
- Alumni, DIA Young Member of Advisory Council of China